LataMed AI Corp. (OTC: LMED) announced today that it expects to formally submit a corporate action request to FINRA seeking approval of a proposed five-for-one forward stock split, along with proportional increases in authorized common and preferred stock. The company stated that the proposed split is intended to support long-term operational scalability, strategic flexibility, and future growth initiatives as it advances telehealth infrastructure deployment and healthcare analytics integration in emerging markets.
The corporate action would apply proportionally to all issued and outstanding shares, including the Series C Voting Preferred Stock, and does not involve any debt restructuring or reduction in shareholder ownership percentages. No fractional shares are expected to be issued, as any fractional interests would be rounded up to the nearest whole share.
Management emphasized that the forward stock split is part of a broader effort to align the company's capital structure with its transition into digital healthcare infrastructure and artificial intelligence-driven telehealth operations. Dr. Kevin Rodan Levy, CEO of LataMed AI, stated, "As we continue advancing our operational and commercialization initiatives throughout Latin America, we believe this proposed forward stock split and proportional capital structure expansion may support broader long-term strategic flexibility, operational scalability, and future growth initiatives."
The company recently announced the commencement of initial operational activities for its telehealth platform in Venezuela, following regulatory authorization from the Ministerio del Poder Popular para la Salud and Servicio Autonomo de Contraloria Sanitaria (SACS). This development marks a significant milestone in LataMed's strategy to deploy scalable healthcare technology in underserved markets.
The proposed stock split remains subject to FINRA review and approval, with no assurance regarding timing or ultimate effectiveness. The company's forward-looking statements highlight risks including FINRA approval delays, regulatory hurdles in emerging markets, and its status as a development-stage enterprise without current revenues.
For more information, visit https://latamed.ai or review SEC filings at www.sec.gov.
